Rhumbline Advisers Decreases Stock Holdings in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX)

Rhumbline Advisers lowered its position in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) by 57.8% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 7,246 shares of the specialty pharmaceutical company’s stock after selling 9,920 shares during the period. Rhumbline Advisers owned approximately 0.06% of Eagle Pharmaceuticals worth $41,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently made changes to their positions in the stock. Vanguard Group Inc. lifted its position in shares of Eagle Pharmaceuticals by 0.4% during the first quarter. Vanguard Group Inc. now owns 640,754 shares of the specialty pharmaceutical company’s stock valued at $3,358,000 after buying an additional 2,630 shares during the last quarter. Headlands Technologies LLC raised its stake in shares of Eagle Pharmaceuticals by 75.7% during the 1st quarter. Headlands Technologies LLC now owns 6,641 shares of the specialty pharmaceutical company’s stock worth $35,000 after buying an additional 2,861 shares during the period. Price T Rowe Associates Inc. MD purchased a new stake in shares of Eagle Pharmaceuticals during the first quarter worth about $83,000. Aristides Capital LLC purchased a new position in shares of Eagle Pharmaceuticals in the fourth quarter valued at approximately $86,000. Finally, DGS Capital Management LLC raised its position in shares of Eagle Pharmaceuticals by 442.5% in the first quarter. DGS Capital Management LLC now owns 61,944 shares of the specialty pharmaceutical company’s stock valued at $325,000 after buying an additional 50,525 shares during the last quarter. 85.36% of the stock is currently owned by institutional investors.

Eagle Pharmaceuticals Stock Performance

NASDAQ:EGRX opened at $3.56 on Wednesday. Eagle Pharmaceuticals, Inc. has a fifty-two week low of $3.21 and a fifty-two week high of $15.69. The company has a 50 day moving average price of $4.46 and a 200 day moving average price of $4.63. The stock has a market capitalization of $46.23 million, a P/E ratio of 2.97 and a beta of 0.53.

Wall Street Analysts Forecast Growth

Separately, StockNews.com started coverage on shares of Eagle Pharmaceuticals in a research report on Thursday, September 26th. They set a “hold” rating on the stock.

Eagle Pharmaceuticals Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.